We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Commercialization and research and development expenses kept BioMarin in the red for years despite multiple approved products, but we're confident in the durable, profit-generating power of its ...

Though BioMarin’s portfolio comprises eight marketed products, its top line is likely to have been driven by key drugs Voxzogo, Naglazyme and Vimizim. Since its commercial launch in 2021 ...

BioMarin’s revenue largely comes from a few key products, notably Voxzogo and enzyme therapies. It has achieved strong growth through regulatory approvals and market expansion initiatives ...

The company is known for products like Voxzogo, designed to treat achondroplasia, and various enzyme therapies for rare genetic disorders. Recently, BioMarin's focus has been on expanding ...

The outcome of clinical trials and regulatory decisions for these competing products could impact BioMarin's market position in the coming years. Want deeper insights into BioMarin's competitive ...

including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and development. Results may differ ...

including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ ...